1021 Biogen earnings
BioCentury & Getty Images

Product Development

Aducanumab looms larger after Biogen cuts guidance, shelves programs in MS and SMA 

Pressure on aducanumab heats up as Biogen submits an MAA to EMA

The pressure on aducanumab heats up as Biogen submits an MAA to EMA.

Oct 21, 2020 | 8:08 PM GMT

Read the full 495 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE